Privacy Policy

Updated 07/09/2023

This Privacy Policy explains what we do with your personal data. It describes how we collect, use and process your personal data, and how, in doing so, we comply with our legal obligations to you. Your privacy is important to us, and we are committed to protecting and safeguarding your data privacy rights.

This Privacy Policy applies to the personal data of Customers, Distributors, Suppliers, Job Applicants, Website Users and other people whose personal data may be processed, such as the emergency contacts and dependents of our Employees. To be clear, if you are an Employee, you should refer to the Genus Employee Privacy Policy which is available on Helix, the Genus intranet.

This Privacy Policy applies to personal data processed by Genus plc or an Associated Company (“Genus” or “us”). For the purpose of applicable data protection legislation, including but not limited to the General Data Protection Regulation (Regulation (EU) 2016/679) (the “GDPR”) and South Africa’s Protection of Personal Information Act 4 of 2013 (“POPIA”), the company responsible for your personal data can be found here. Please note that references to “Genus” should be read as “PIC” or “ABS” as relevant depending on which Genus Associated Company you are interacting with.

It is important to point out that we may amend this Privacy Policy from time to time. Please just visit this page if you want to stay up to date, as we will post any changes here.

If you are dissatisfied with any aspect of our Privacy Policy, you may have legal rights. We have described these as well where relevant.

This Privacy Policy applies in relevant countries throughout our European network. Different countries may approach data privacy in slightly different ways and so we may also have country-specific parts to this Privacy Policy. You can find country-specific terms for your jurisdiction below. This allows us to ensure that we’re complying with all applicable data privacy protections.

All claims about safety and efficacy of PIC's PRRS-resistant pig are currently being evaluated by the US FDA.